{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T22:04:00Z","timestamp":1769551440142,"version":"3.49.0"},"reference-count":20,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,3,20]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>We report the case of an early adolescent male on lamotrigine and levetiracetam therapy with a 1-month history of progressive, bilateral, painless visual loss which resolved on cessation of lamotrigine. To our knowledge, we present the first case of lamotrigine and levetiracetam dual therapy associated with toxic optic neuropathy, supported by electrophysiology and optical coherence tomography (OCT) changes. Electrophysiology findings were consistent with retinal ganglion cell dysfunction, with bilateral optic nerve involvement. Macula OCT showed mild retinal ganglion cell loss in all inner quadrants bilaterally. This case highlights the importance of asking patients with epilepsy treated with lamotrigine and levetiracetam about visual problems and considering early dose reduction or cessation of treatment.<\/jats:p>","DOI":"10.1136\/bcr-2023-256961","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T14:20:59Z","timestamp":1711549259000},"page":"e256961","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Toxic optic neuropathy associated with lamotrigine and levetiracetam dual therapy"],"prefix":"10.1136","volume":"17","author":[{"given":"Munazzah","family":"Chou","sequence":"first","affiliation":[{"name":"Ophthalmology, Guy's and St Thomas' National Health Service Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily","family":"Lai","sequence":"additional","affiliation":[{"name":"Ophthalmology, Guy's and St Thomas' National Health Service Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3859-0865","authenticated-orcid":false,"given":"Magella","family":"Neveu","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2495-7571","authenticated-orcid":false,"given":"Ailsa","family":"Ritchie","sequence":"additional","affiliation":[{"name":"Ophthalmology, Guy's and St Thomas' National Health Service Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"key":"2025082712355050000_17.3.e256961.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(03)00082-7"},{"key":"2025082712355050000_17.3.e256961.2","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.5301\/ejo.5000674","article-title":"Lamotrigine-induced tubulointerstitial nephritis and uveitis-atypical Cogan syndrome","volume":"26","author":"Kolomeyer","year":"2015","journal-title":"Eur J Ophthalmol"},{"key":"2025082712355050000_17.3.e256961.3","first-page":"7","article-title":"Lamotrigine associated retinal photoxicity","volume":"56","author":"Harris","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025082712355050000_17.3.e256961.4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.seizure.2022.01.011","article-title":"Eye disorders associated with newer antiepileptic drugs: a real-world disproportionality analysis of FDA adverse event reporting system","volume":"96","author":"Hu","year":"2022","journal-title":"Seizure"},{"key":"2025082712355050000_17.3.e256961.5","unstructured":"Maertens P , Dees D . Levetiracetam-induced optic neuropathy. Abstract number: 2.195, Submission category: 7. Antiepileptic drugs, year: 2009, submission ID: 9904. 2009. Available: www.aesnet.org [Accessed 26 Aug 2009]."},{"key":"2025082712355050000_17.3.e256961.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60460-7"},{"key":"2025082712355050000_17.3.e256961.7","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/j.1528-1167.2005.43204.x","article-title":"Retinal electrophysiological results in patients receiving lamotrigine monotherapy","volume":"46","author":"Arndt","year":"2005","journal-title":"Epilepsia"},{"key":"2025082712355050000_17.3.e256961.8","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-242496","article-title":"Unusual side effects of levetiracetam","volume":"14","author":"Badarny","year":"2021","journal-title":"BMJ Case Rep"},{"key":"2025082712355050000_17.3.e256961.9","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.toxrep.2021.08.005","article-title":"Correlation of elevated lamotrigine and levetiracetam serum\/plasma levels with toxicity: a long-term retrospective review at an academic medical center","volume":"8","author":"Wood","year":"2021","journal-title":"Toxicol Rep"},{"key":"2025082712355050000_17.3.e256961.10","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X19666210826125341"},{"key":"2025082712355050000_17.3.e256961.11","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/WNO.0000000000000609","article-title":"Vigabatrin: lessons learned from the United States experience","volume":"38","author":"Foroozan","year":"2018","journal-title":"J Neuroophthalmol"},{"key":"2025082712355050000_17.3.e256961.12","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1529-8027.2011.00355.x","article-title":"Levetiracetam exhibits protective properties on rat Schwann cells in vitro","volume":"16","author":"Stettner","year":"2011","journal-title":"J Peripher Nerv Syst"},{"key":"2025082712355050000_17.3.e256961.13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/15569527.2020.1778016","article-title":"Retinal ganglion cell complex and visual evoked potentials in levetiracetam treatment","volume":"39","author":"Hazirolan","year":"2020","journal-title":"Cutan Ocul Toxicol"},{"key":"2025082712355050000_17.3.e256961.14","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00381-019-04076-5","article-title":"An investigation of the ocular toxic effects of levetiracetam therapy in children with epilepsy","volume":"35","author":"Diler Durgut","year":"2019","journal-title":"Childs Nerv Syst"},{"key":"2025082712355050000_17.3.e256961.15","article-title":"Effect of levetiracetam on ocular perfusion measure with optical coherence tomography angiography","volume":"87","author":"Kaderli","year":"2023","journal-title":"Arq Bras Oftalmol"},{"key":"2025082712355050000_17.3.e256961.16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/bcpt.13203","article-title":"Lamotrigine drug interactions in combination therapy and the influence of therapeutic drug monitoring on clinical outcomes in paediatric patients","volume":"125","author":"Koristkova","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2025082712355050000_17.3.e256961.17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2005.01.005","article-title":"Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials","volume":"64","author":"Gidal","year":"2005","journal-title":"Epilepsy Res"},{"key":"2025082712355050000_17.3.e256961.18","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.mito.2018.07.007","article-title":"Toxic medications in Leber's hereditary optic neuropathy","volume":"46","author":"Kogachi","year":"2019","journal-title":"Mitochondrion"},{"key":"2025082712355050000_17.3.e256961.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2010.11.002"},{"key":"2025082712355050000_17.3.e256961.20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3109\/08820538.2010.500267","article-title":"Cuban epidemic optic neuropathy and its relationship to toxic and hereditary optic neuropathy","volume":"25","author":"Santiesteban-Freixas","year":"2010","journal-title":"Semin Ophthalmol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-256961","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:35:58Z","timestamp":1756323358000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-256961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,27]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/bcr-2023-256961"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-256961","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}